BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32782369)

  • 1. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
    Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
    Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Shin JW; Jeong J; Jung SW; Lee SB; Park BR; Kim MJ; Park EJ; Park NH
    Dig Dis Sci; 2021 May; 66(5):1739-1750. PubMed ID: 32524416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
    Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
    Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
    Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
    Choi H; Seo GH
    J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
    Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
    Jeong S; Shin HP; Kim HI
    Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
    Ha NB; Trinh HN; Rosenblatt L; Nghiem D; Nguyen MH
    J Clin Gastroenterol; 2016 Feb; 50(2):169-74. PubMed ID: 26018133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.